Fort Wayne Neurological Center

Fort Wayne, Indiana IN 46804

0 studies enrolling now · 49 studies all time

What they study most

Acute Migraine, Alzheimer Disease, Alzheimer's Disease, Autoimmune Diseases of the Nervous System, Brain Atrophy, Brain Infarction, Cataplexy, Cerebral Ischemia, Dementia, Disease Progression, Early Alzheimer's Disease, Epilepsy

Studies at this site

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. — Completed
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects — Stopped early
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) — Completed
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache — Completed
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS) — Completed
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
Bryostatin Treatment of Moderately Severe Alzheimer's Disease — Completed
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis — Stopped early
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension — Completed
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine — Completed
Randomized Trial in Adult Participants With Acute Migraines — Completed
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy — Completed
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study — Stopped early
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) — Stopped early
Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension — Completed
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants — Completed
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia — Stopped early
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease — Completed
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy — Completed
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma — Completed
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis — Completed
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) — Stopped early
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy — Completed
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis — Completed
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — NO_LONGER_AVAILABLE
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis — Completed
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke — Stopped early
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects — Completed
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations — Completed
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis — Completed
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder — Completed
Effects of ONO-2506PO in Patients With Alzheimer's Disease — Completed
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke — Stopped early
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis — Completed
Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients — Completed